Insight

Stephen V Liu Shared ORCHARD Study Results on Osimertinib Plus Necitumumab in EGFR-Mutated NSCLC Published in JCO

Stephen V Liu/X

Jun 8, 2025, 16:34

Stephen V Liu Shared ORCHARD Study Results on Osimertinib Plus Necitumumab in EGFR-Mutated NSCLC Published in JCO

Stephen V Liu, Associate Professor of Medicine at Georgetown University, shared a post on X:

“Results from Osimertinib + Necitumumab module of phase II ORCHARD study published in JCO.

Patients with EGFR-Mutated NSCLC with progression on osi and EGFR amplification or secondary EGFR mt received Osimertinib 80mg + Necitumumab D1/8 q21d. RR 11%, PFS 4m, OS 11.4m, 53% had G3+ AE.”

Title: ORCHARD: Osimertinib Plus Necitumumab in Patients With Epidermal Growth Factor Receptor–Mutated Advanced Non–Small Cell Lung Cancer With a Secondary Epidermal Growth Factor Receptor Alteration Whose Disease Had Progressed on First-Line Osimertinib

Journal: JCO

Authors: Jonathan W. Riess, Adrianus J. de Langen, Santiago Ponce, Sarah B. Goldberg, Zofia Piotrowska, Jonathan W. Goldman, Xiuning Le, Byoung Chul Cho, Yasuto Yoneshima, Helen Ambrose, Riccardo Cavazzina, Kwan Ho Tang, James Lau, Helena A. Yu

Read the full article.

ORCHARD

Adrianus J de Langen Byoung Chul Cho cancer EGFR-mutated NSCLC Georgetown University Helen Ambrose Helena A. Yu James Lau Jonathan W. Goldman Jonathan W. Riess Kwan Ho Tang Necitumumab OncoDaily Oncology ORCHARD osimertinib Riccardo Cavazzina Santiago Ponce Sarah B. Goldberg Stephen V Liu Xiuning Le Yasuto Yoneshima Zofia Piotrowska

FDA Accepts NDA for Vepdegestrant in ESR1-Mutant ER+/HER2- Advanced Breast Cancer

Hubert Caron Retires from Roche-Genentech

Ramy Sedhom: Palliative Care Isn’t Just about When. It’s about Who, What, and How

Miriam Mutebi: One Small Grant, One Big Difference

Jasmine Kamboj: How We Bring Ourselves to the Table as Leaders